{"schema_version":"secwatch.filing_event.v1","accession":"0001125345-24-000061","form_type":"8-K","ticker":"MGNX","cik":"0001125345","company_name":"MACROGENICS INC","filed_at":"2024-03-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.461004+00:00","generated_at":"2026-06-05T01:08:39.931408+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"MacroGenics reports FY2023 net loss of $9.1M; cash $229.8M; vobra duo data at ASCO 2024","bullets":["Net loss $9.1M vs $119.8M in 2022; revenue $58.7M (down 61% YoY) due to lower collaboration revenue.","Cash, equivalents & securities $229.8M as of Dec 31, 2023, up from $154.3M; cash runway into 2026.","Preliminary TAMARACK Phase 2 data for vobra duo in mCRPC expected at ASCO 2024; 177 patients enrolled.","Initiated Phase 1 dose escalation of MGC026 (topoisomerase I inhibitor-based ADC) in advanced solid tumors.","Received $100M from sale of TZIELD royalty interest and $50M milestone from Sanofi, recorded as $150.9M gain."],"urls":{"canonical":"https://secwatch.observer/filing/0001125345-24-000061","json":"https://secwatch.observer/filing/0001125345-24-000061.json","markdown":"https://secwatch.observer/filing/0001125345-24-000061.md","text":"https://secwatch.observer/filing/0001125345-24-000061.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1125345/000112534524000061/0001125345-24-000061-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1125345/000112534524000061/mgnx-20240307.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T01:08:39.931408+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"39d07caaf191f7a56dff2968d4064d2d6f3608e4","claim":"MACROGENICS INC reported financial results for the year ended December 31, 2023.","evidence_excerpt":"On March 7, 2024, MacroGenics, Inc. (the \"Company\") announced financial and operating results as of and for the year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1125345/000112534524000061/0001125345-24-000061-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}